Literature DB >> 25290430

Separation of self from non-self in the complement system.

J P Atkinson1, T Farries.   

Abstract

The alternative complement pathway is a self-contained and independent recognition and effector pathway that evolved to protect the host from microbes. As such, it must separate self from non-self. Via low grade continuous turnover (tickover) of the pivotal C3 component, the alternative complement pathway is always on guard to defend the host. Activated C3 binds continuously to self tissue and to foreign tissue, if present. There is no apparent discrimination at this initiation step. However, the amplification of C3 deposition on self (but not foreign) tissue, a necessity in establishing the effector functions of this pathway, is inhibited by a series of functionally, structurally and genetically related plasma and membrane glycoproteins which down-regulate complement activation. These regulatory molecules are widely distributed on human tissue. The plasma proteins are preferentially active on fluid-phase components while membrane-bound forms act on cell-bound components. Here, John Atkinson and Timothy Farries discuss these inhibitors of complement activation and suggest that their action explains the ability of the alternative pathway to amplify on foreign tissue but be down-regulated on autologous tissue.
Copyright © 1987. Published by Elsevier B.V.

Entities:  

Year:  1987        PMID: 25290430     DOI: 10.1016/0167-5699(87)90167-8

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  21 in total

1.  Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

2.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

3.  Species selective interaction of Alphaherpesvirinae with the "unspecific" immune system of the host.

Authors:  H P Huemer; C Larcher; S van Drunen Littel-van den Hurk; L A Babiuk
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  Complement activation in Mycoplasma fermentans-induced mycoplasma clearance from infected cells: probing of the organism with monoclonal antibodies against M161Ag.

Authors:  S Kikkawa; M Matsumoto; T Sasaki; M Nishiguchi; K Tanaka; K Toyoshima; T Seya
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H.

Authors:  D Kraus; M E Medof; C Mold
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 6.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

7.  Systemic complement activation following human acute ischaemic stroke.

Authors:  E D Pedersen; U Waje-Andreassen; C A Vedeler; G Aamodt; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  Activated C3 (C3b) in the nephritic glomerulus.

Authors:  C Pan; C F Strife; A J McAdams; C D West
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

9.  Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.

Authors:  Jan-Michael Abicht; Ioannis Kourtzelis; Bruno Reichart; Sophia Koutsogiannaki; Alexandra Primikyri; John D Lambris; Triantafyllos Chavakis; Lesca Holdt; Alexander Kind; Sonja Guethoff; Tanja Mayr
Journal:  Xenotransplantation       Date:  2016-09-27       Impact factor: 3.907

10.  High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?

Authors:  P Hofman; B L Hsi; S Manie; P Fenichel; A Thyss; B Rossi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.